Cocrystal Pharma presented CDI-988, a potential first oral antiviral for norovirus infection, at the 9th International Calicivirus Conference.
The company highlighted CDI-988's mechanism of action and promising Phase 1 study results at the conference.
CDI-988, developed with Cocrystal's proprietary technology, shows broad-spectrum antiviral activity against multiple norovirus genogroups.
CDI-988: Potential Game-Changer
CDI-988 represents a significant advancement as the first oral antiviral for prevention and treatment of norovirus infection.
Clinical Progress and Milestones
The recent completion of Phase 1 study and FDA's IND clearance mark key milestones in CDI-988's clinical development.
Safety and Efficacy Profile
CDI-988 exhibited a favorable safety profile in human intestinal tissue with no serious adverse events reported in Phase 1 trials.
- CDI-988's high exposure in the small intestine suggests a potential GI-targeted antiviral for norovirus infection.
- The FDA authorization for a Phase 1b human challenge study reflects progress towards evaluating CDI-988 for norovirus prophylaxis and treatment.
Cocrystal Pharma's CDI-988 shows promise as a groundbreaking oral antiviral for norovirus, with significant safety and efficacy data backing its development. The company's innovative approach and regulatory progress position CDI-988 as a potential game-changer in antiviral therapeutics.